@article{7a2782b1da9c47c68866ad17dc7736f5,
title = "Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy",
abstract = "Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.",
keywords = "Aged, Blood Glucose, Body Composition, Bone Density, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, PPAR gamma, Quinazolines, Thiazolidinediones, Water-Electrolyte Balance, Weight Gain",
author = "Kim Henriksen and Inger Byrjalsen and Per Qvist and Henning Beck-Nielsen and Gitte Hansen and Riis, {Bente J} and Hans Perrild and Svendsen, {Ole Lander} and Jeppe Gram and Karsdal, {Morten A} and Claus Christiansen and {BALLET Trial Investigators}",
note = "Copyright {\textcopyright} 2011 John Wiley & Sons, Ltd.",
year = "2011",
doi = "10.1002/dmrr.1187",
language = "English",
volume = "27",
pages = "392--401",
journal = "Diabetes - Metabolism: Research and Reviews (Print Edition)",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "4",
}